Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer

Future Oncology ◽

10.2217/fon-2018-0027 ◽

2018 ◽

Vol 14 (18) ◽

pp. 1875-1882 ◽

Cited By ~ 3

Author(s):

Shirish M Gadgeel

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

PCN36 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in Germany

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.086 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations

Value in Health ◽

10.1016/j.jval.2012.08.2122 ◽

2012 ◽

Vol 15 (7) ◽

pp. A424

Author(s):

P. Garrido ◽

G. López-Vivanco ◽

R. Rosell ◽

B. Espinós ◽

A. Castro-Gomez

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Activating Mutations ◽

Effectiveness Analysis ◽

Platinum Based Chemotherapy ◽

Optimal and Ensure Trials - Based Combined Cost-Effectiveness Analysis of Erlotinib Versus Chemotherapy for the First- Line Treatment of Asian Patients with Nonsquamous Non– Small-Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2016.08.274 ◽

2016 ◽

Vol 19 (7) ◽

pp. A888-A889

Author(s):

F Wen ◽

H Zheng ◽

P Zhang ◽

DW Hutton ◽

Q Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s293983 ◽

2021 ◽

Vol Volume 13 ◽

pp. 4263-4270

Author(s):

Longfeng Zhang ◽

Na Li ◽

Maobai Liu ◽

Bin Zheng ◽

Zhijuan Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Journal of Thoracic Disease ◽

10.21037/jtd.2017.04.43 ◽

2017 ◽

Vol 9 (5) ◽

pp. E447-E450

Author(s):

Ikuo Sekine

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.087 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2020-002208 ◽

2020 ◽

pp. ejhpharm-2020-002208

Author(s):

Yuan Jiang ◽

Xingwei Wang

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

Effectiveness Analysis ◽